Sobi and Apellis Pharmaceuticals report promising results for pegcetacoplan in phase 2 NOBLE study
Sobi and Apellis Pharmaceuticals, Inc. have announced encouraging one-year outcomes from the phase 2 NOBLE study, investigating the efficacy of systemic pegcetacoplan for treating post-transplant ... Read More
Apellis to submit NDA for intravitreal pegcetacoplan to FDA in H1 2022
Apellis Pharmaceuticals said that it is on track to submit a new drug application (NDA) for its intravitreal pegcetacoplan to the US Food and Drug ... Read More
Apellis reports positive results for pegcetacoplan in phase 2 C3G trial
Apellis Pharmaceuticals has reported positive results for pegcetacoplan from the phase 2 DISCOVERY clinical trial in patients with C3 glomerulopathy (C3G), a type of kidney ... Read More